OrthoPediatrics (NASDAQ:KIDS) Coverage Initiated at Lake Street Capital

Stock analysts at Lake Street Capital assumed coverage on shares of OrthoPediatrics (NASDAQ:KIDS) in a note issued to investors on Monday. The brokerage set a “buy” rating and a $37.00 price target on the stock. Lake Street Capital’s price objective points to a potential upside of 63.00% from the company’s current price.

KIDS has been the topic of a number of other research reports. Stifel Nicolaus cut their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Needham & Company LLC reissued a “buy” rating and issued a $42.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, March 5th. Finally, Truist Financial decreased their target price on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, OrthoPediatrics has an average rating of “Moderate Buy” and a consensus price target of $37.20.

OrthoPediatrics Stock Performance

Shares of NASDAQ KIDS opened at $22.70 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. OrthoPediatrics has a one year low of $21.02 and a one year high of $35.99. The business’s 50-day moving average price is $24.50 and its two-hundred day moving average price is $24.97. The company has a market capitalization of $551.31 million, a P/E ratio of -18.46 and a beta of 1.16.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.67 million during the quarter, compared to analyst estimates of $51.16 million. During the same period in the previous year, the company earned ($0.23) EPS. Analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current fiscal year.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the sale, the chief executive officer now directly owns 319,155 shares in the company, valued at $7,934,193.30. This trade represents a 2.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $132,006.60. Following the transaction, the general counsel now directly owns 110,767 shares of the company’s stock, valued at $2,753,667.62. This represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,732 shares of company stock worth $589,978 in the last 90 days. 31.80% of the stock is owned by company insiders.

Institutional Trading of OrthoPediatrics

Institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP lifted its position in OrthoPediatrics by 20.2% in the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company’s stock worth $24,601,000 after purchasing an additional 178,078 shares during the period. Wasatch Advisors LP lifted its holdings in shares of OrthoPediatrics by 47.2% during the 4th quarter. Wasatch Advisors LP now owns 696,318 shares of the company’s stock worth $16,141,000 after acquiring an additional 223,217 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of OrthoPediatrics by 29.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company’s stock valued at $15,576,000 after acquiring an additional 152,681 shares in the last quarter. AWM Investment Company Inc. increased its stake in OrthoPediatrics by 14.8% in the fourth quarter. AWM Investment Company Inc. now owns 516,794 shares of the company’s stock valued at $11,979,000 after acquiring an additional 66,779 shares during the period. Finally, Millennium Management LLC bought a new stake in OrthoPediatrics in the fourth quarter valued at about $9,798,000. 69.05% of the stock is currently owned by institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.